In many protein kinases, a characteristic conformational change (the ''DFG flip'') connects catalytically active and inactive conformations. Many kinase inhibitors-including the cancer drug imatinib-selectively target a specific DFG conformation, but the function and mechanism of the flip remain unclear. Using long molecular dynamics simulations of the Abl kinase, we visualized the DFG flip in atomiclevel detail and formulated an energetic model predicting that protonation of the DFG aspartate controls the flip. Consistent with our model's predictions, we demonstrated experimentally that the kinetics of imatinib binding to Abl kinase have a pH dependence that disappears when the DFG aspartate is mutated. Our model suggests a possible explanation for the high degree of conservation of the DFG motif: that the flip, modulated by electrostatic changes inherent to the catalytic cycle, allows the kinase to access flexible conformations facilitating nucleotide binding and release.
conformational change ͉ DFG motif ͉ imatinib ͉ molecular dynamics simulation ͉ pH dependence N early 2% of human genes encode protein kinases (1) , enzymes involved in almost all aspects of cellular regulation, which use ATP to phosphorylate protein substrates and release ADP as a byproduct. Given the importance of protein kinases to cell growth, movement, and death, it is not surprising that the protein kinase catalytic domain is the protein domain most commonly encoded by known cancer genes (2) , and that protein kinases constitute one of the largest families of drug targets (3) .
Lying within nearly every eukaryotic protein kinase domain, adjacent to the ATP-binding site, is a sequence of 3 residues, Asp-Phe-Gly (DFG). The reasons for the conservation of these residues are not fully understood, but the motif is known to be highly important, as was recently highlighted by the identification of potential ''driver'' mutations in human cancers at the DFG motif in 8 different kinases (4) . The DFG aspartate is believed to be important for catalysis, and indeed typically points into the ATPbinding site (the DFG-in conformation), where it can coordinate an ATP-bound magnesium ion (5, 6) . In a diverse subset of protein kinases, however, including c-Abl, IRK, c-Kit, Flt3, Csk, RAF, and P38, the DFG motif can also adopt a dramatically different conformation in which the DFG aspartate and phenylalanine side chains swap positions, leaving the aspartate pointing away from the binding site (the DFG-out conformation). The conformational change connecting the DFG-in and DFG-out conformations (a ''DFG flip''; see Fig. 1 ) involves a Ϸ10-Å change in the positions of the 2 side chains.
The DFG flip (see Movie S1) is a central feature of the activation of the nonreceptor tyrosine kinase c-Abl, which before activation is held in an inactive DFG-out conformation by an autoinhibitory interaction with its regulatory domains (7) . The DFG flip underlies the success of the cancer drug imatinib, which binds to the DFG-out conformation of the aberrant gene fusion product BCR-Abl (8) and has proven remarkably efficacious in the clinical treatment of chronic myeloid leukemia and certain other cancers (9, 10) . The ability of imatinib to specifically recognize the DFG-out conformation of BCR-Abl has been credited for imatinib's selectivity, and intensive searches are now under way for other kinase inhibitors that selectively bind to DFG-out conformations (11, 12) .
Knowledge of the detailed mechanism and driving forces of DFG conformational change would deepen our understanding of kinase activation and open new directions in drug discovery. However, it is very challenging to directly probe the dynamics of this motif experimentally (13) . Molecular dynamics (MD) simulation provides an alternative means to study kinase dynamics (14) (15) (16) , but the time scale accessible to such studies has typically been restricted to between 100 ps and 10 ns. Observation of the DFG flip at such short time scales has required the introduction of artificial biasing forces (17) , which can generate nonphysical trajectories and obscure the forces that actually drive the flip. In the work reported here, we used recently developed algorithms for the high-speed, parallel execution of MD simulations (18) (19) (20) (21) to perform unbiased MD simulations, each hundreds of nanoseconds in length, of a construct Author contributions: Y.S., J.K., and D.E.S. designed research; Y.S., M.A.S., and F.F. performed research; Y.S., M.A.S., M.P.E., and H.X. analyzed data; and Y.S., M.A.S., M.P.E., M.Ø.J., R.O.D., J.K., and D.E.S. wrote the paper.
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of human c-Abl containing only the kinase domain. (Because the kinase domains of c-Abl and BCR-Abl are identical in sequence, we refer to this common domain below as simply ''Abl.'') Our analysis of these simulations allowed us to formulate a model of key dynamic, energetic, and structural factors involved in DFG flips. To validate our model experimentally, we used fluorescence assays of Abl-imatinib binding to probe DFG conformation, the results of which confirmed our central computational findings.
Like other eukaryotic protein kinase domains, Abl consists of a smaller N-terminal lobe and a larger C-terminal lobe (the N-lobe and the C-lobe, respectively), with the ATP-binding site located between them. The N-lobe is composed of 5 ␤-strands and a helix referred to as ␣C, whereas the C-lobe is predominantly helical. The DFG motif borders the ATP-binding site and is located between the 2 lobes, at the N terminus of a flexible segment known as the activation loop. Fig. 1 A and C shows Abl adopting DFG-in (22) and DFG-out (7) conformations, respectively, whereas Fig. 1B shows an important intermediate conformation observed in our simulations of the DFG flip. This conformation differs from the other 2 in that helix ␣C is displaced away from the binding site (the ␣C-out conformation, by contrast with the ␣C-in conformation shown in Fig. 1 A and C) . A recently solved crystal structure of Abl also adopts an ␣C-out conformation, which has been suggested as a potential intermediate in the DFG flip (17) . Although kinases in their active states adopt ␣C-in conformations, many kinases in their inactive states are known to adopt ␣C-out conformations, first defined in Cdk (23) and Src (24, 25) kinases, but now seen in many others-including EGFR (26) , whose ␣C-out conformation is recognized by the cancer drug lapatinib. Thus, just as many kinases can access alternative conformations through a DFG flip, many kinases can access alternative conformations through a transition between ␣C-in and ␣C-out conformations.
To study the conformational changes associated with the DFG flip without introducing any biasing forces in our MD simulations, we ''loosened'' helix ␣C by mutating to alanine a methionine residue that previous studies suggested might be involved in stabilizing hydrophobic interactions between helix ␣C and the remainder of the protein. In our simulations of the resulting protein, we were able to observe the DFG flip and its coupling with helix-␣C motion at an atomic level of detail. Analysis of these simulations led us to propose an energetic model in which the protonation state of Asp-381, which is influenced by local electrostatic interactions, serves as the switch that controls the flip. On the basis of our simulation results, we made certain predictions regarding the pH dependence of Abl-imatinib binding, then performed fluorescence quenching experiments to test these predictions. The results of these experiments were consistent with our model (and also allowed us to estimate the time scale of the DFG flip to be tens of milliseconds). Our findings could be interpreted as providing mechanistic support for the suggestion (27) that the DFG flip plays a significant role in the catalytic cycle of protein kinases by facilitating nucleotide binding and release.
Results and Discussion
Simulations of Abl. We performed a total of Ͼ2 s of all-atom MD simulations of Abl in explicit water, using the OPLS-AA/L force field (28, 29) for proteins, with most individual simulations between 100 and 300 ns in length. All simulations were performed at constant temperature (300 K) and pressure (1 bar); see SI Text. (22) ], the DFG aspartate has an elevated pK a . In a DFG-out structure of Abl [PDB ID code 1OPK (7)] the DFG aspartate appears to be protonated and hydrogen bonded to a backbone carbonyl group. These observations led us to hypothesize that the protonation of the DFG aspartate might be an important determinant of DFG conformation, and we therefore performed simulations with the residue in different protonation states. We started 4 simulations in the active DFG-in conformation, including 2 (simulations 1a and 1b in Table  S1 ) with Asp-381 protonated and 2 with Asp-381 deprotonated (simulations 2a and 2b). No DFG flip was observed in these simulations, suggesting that its time scale is much longer than the several hundred nanoseconds we simulated. This result is consistent with NMR studies of the p38 (13) and PKA (31) kinases, which are suggestive of microsecond-to millisecond-scale DFG motions.
In all 4 simulations, however, substantial motion of helix ␣C was observed, despite the fact that no mutation was introduced to promote such motion. In the simulations with Asp-381 protonated, this motion was particularly pronounced, leading to the formation of the Glu-286-Arg-386 salt bridge characteristic of the ␣C-out conformation and emergence of a hydrophobic pocket (the Npocket; see Fig. 1B ) at the base of the N-lobe near Phe-382 ( Fig.  2A) . The N-pocket, which is contiguous with a region exploited by many drugs (the so-called ''kinase specificity pocket''), has been suggested to play a role in facilitating the DFG flip (17) . Although simulations 1a and 1b showed the transition from ␣C-in to ␣C-out ( Fig. 1) , we did not observe Phe-382 entering into the N-pocket, apparently because of interactions between this residue and the helix-␣C residue Met-290. Likewise, we did not observe Phe-382 and Met-290 to adopt the exchanged positions they assume in crystal structures of Abl and Src kinases in ␣C-out conformations. These residues remained, for the most part, closely packed during the simulations (Fig. S1 ), and when they were briefly driven apart by thermal fluctuations, Met-290 remained a steric barrier at the entrance to the N-pocket (Fig. 2 A) .
To lower this barrier, we attempted to further increase the extent of motion of helix ␣C by introducing an M290A mutation. Met-290 is not a conserved residue in protein kinases, and the c-Src mutant corresponding to M290A maintains substantial activity (Fig. S2B) . In Abl, Met-290 is part of a ''hydrophobic spine'' that stabilizes the active conformation (32), and we anticipated that the M290A mutation might therefore facilitate entry of Phe-382 into the N-pocket by allowing a larger range of motion of helix ␣C, as well as by directly reducing the size of the obstructing residue. We 
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A B initiated simulations of the M290A mutant with the DFG aspartate both protonated (simulations 3 a-e) and deprotonated (4 a and b).
With the M290A mutation, Phe-382 was indeed observed entering and leaving the N-pocket (Fig. 2b) , with maximum residence times of 6 and 25 ns in simulations 4a and 4b, respectively. These results support the structural observation that Met-290 presents a barrier to the entry of Phe-382 into the N-pocket. Protonation of Asp-381 also appears to be a factor, because none of the simulations 3 a-e showed Phe-382 entering the N-pocket, presumably because of an indirect coupling between the (protonation-dependent) conformation of Asp-381 and the conformation of Phe-382. This failure of Phe-382 to enter the N-pocket when Asp-381 is protonated, however, may well be due to the limited simulation time scale, over which Asp-381 is trapped by a hydrogen bond (with Asp-363).
Simulations of the DFG-in to DFG-out Flip. Because the DFG-in conformation with Phe-382 in the N-pocket (Fig. 1b) may be an important intermediate of the DFG flip (17), we initiated 4 simulations of the M290A mutant from this conformation (taken from simulation 4a). In 2 simulations (5 a and b) Asp-381 was deprotonated and the DFG flip was not observed. In the other 2 simulations (6 a and b), Asp-381 was protonated and the DFG flip was observed after 68 and 76 ns, respectively. In our simulations, the M290A mutation was found to be required for Phe-382 to enter the N-pocket, but once this conformation had been reached, the DFG flip occurred even in the absence of this mutation. This was shown in simulation 7, which started from the same conformation, with Asp-381 protonated and Ala-290 mutated back to methionine; the DFG flip was observed after 33 ns. The 3 observed DFG flips followed similar pathways, as described below. Fig. 3A shows a sequence of simulation conformations to illustrate the DFG flip. The motion of the 2 side chains through the crowded environment resembles a crankshaft motion around the main chain, and the DFG main chain also undergoes conformational rearrangement as an integral part of the flip (Fig. 3B) .
The simulations indicate that large-scale motions play a key role in enabling the bulky side chain of Phe-382 to enter the ATPbinding site. Before the flip, we observe significant twisting and hinge-opening motions of the N-lobe with respect to the C-lobe, along with further outward displacement of helix ␣C leading to an ␣C-out conformation (Fig. 3) . This leads to conformations in which Phe-382 has access to the ATP-binding site. After completion of the DFG flip, the N-lobe relaxes toward the autoinhibited conformation, and the interlobe motion subsides (Fig. S3) .
A more detailed picture of the local changes occurring during the simulated DFG flip emerges from the examination of certain key dihedral angles. Several angles are different in the active and autoinhibited conformations (Fig. S4B) . Protonation of Asp-381 at the beginning of the simulation causes this residue to reposition toward the C-lobe within the ATP-binding site, which is reflected in a change of its angle. There is subsequently significant motion, including large fluctuations in the angle of Gly-383 and concerted changes in most DFG main-chain dihedral angles (see Fig. S3 ). Until the DFG flip occurs, however, Asp-381 remains in the ATP-binding site and Phe-382 remains in the N-pocket, despite the main chain sometimes adopting DFG-out-like conformations. When the DFG motif finally flips, it is through a similar concerted change in main-chain conformation coupled with Phe-382 swinging into the ATP-binding site by means of a simultaneous change in its 1 angle. The flip itself lasts Ϸ2 ns. Subsequently, the dihedral angles in the DFG motif exhibit much less variation. Such a transition between relatively flexible and rigid states is observed in all 3 simulations in which we saw DFG flips.
Structural details of the DFG flip emerging from our simulations are consistent with existing crystal structures. Analysis of a representative set of kinase crystal structures (33) (see SI Text) shows that they and the simulation structures occupy similar regions of DFG conformational space (Fig. S4B) . In both crystal structures and simulations, Asp-381 is always positioned toward the C-lobe side and Phe-382 toward the N-lobe whenever the DFG motif adopts an intermediate conformation between DFG-in and DFGout. When ordered appropriately, the X-ray structures can even provide an ''animation'' of a DFG flip resembling the trajectory of the simulated conformational change (Fig. S4A) . We now construct a model of the relative free energy of the DFG-in and DFG-out conformations of Abl that can be used to estimate the effects of pH changes on DFG conformation. Although MD simulation could, in principle, be used to approximate such free energies, the aggregate amount of simulation time required to obtain accurate computational estimates using currently available techniques and technologies made this approach infeasible for use in this context. Instead, our model approximately accounts for the factors contributing to each conformation's stability by using empirical hydrophobicity data and a pK a calculation on a static structure.
The most important structural factor embodied in our model is the change in environment of residues Asp-381 and Phe-382 caused by a DFG flip. In the DFG-in conformation, Asp-381 is located among charged and polar residues in the aqueous environment of the ATP-binding site, and Phe-382 is located in a hydrophobic environment. Conversely, after the DFG flip, Phe-382 is in the polar environment of the ATP-binding site, and Asp-381 is in a mostly hydrophobic environment. Because there is a very high free-energy cost to bury a charge in a hydrophobic environment (34), we assume DFG-out conformations to have Asp-381 protonated. Because our simulations point to the importance of the protonation state of this residue, our model contains 3 states: (i) DFG-in, Asp-381 deprotonated; (ii) DFG-in, Asp-381 protonated; and (iii) DFG-out, Asp-381 protonated. At thermodynamic equilibrium at temperature T, the relative population of the DFG-out conformation decreases with increasing pH as (see SI Text) 
where ⌬G 233 is the free-energy cost of the DFG flip from DFG-in to DFG-out with Asp-381 protonated, R is the gas constant, and pK a,in is the pK a of Asp-381 in a DFG-in conformation (i.e., it is the hypothetical pK a when DFG-out states are excluded, and thus differs from the actual pK a ). At equilibrium, one might anticipate DFG-in conformations to dominate, because the aspartate and phenylalanine residues are favorably placed in environments matching their polarity. Three other factors combined, however, may tip the thermodynamic balance in favor of DFG-out conformations. First, in the DFG-out conformation of Abl, which we model on the kinase domain of c-Abl PDB ID code 1OPK (7), Asp-381 is well positioned to form a hydrogen bond with the exposed backbone carbonyl of Val-299. Second, contrary to what one might expect given the preponderance of reported kinase structures that appear in the DFG-in conformation, we find that the -angles of the DFG aspartate in active Abl, and in most other DFG-in kinase structures, fall within the unusual left-handed helix region of Ramachandran space ( Fig.  S4B ), indicating a more strained main-chain configuration for DFG-in than DFG-out. Third, standard electrostatics calculations (30) suggest that Asp-381 has an elevated value of pK a,in in the absence of the ATP-bound magnesium ion, due in part to the influence of the conserved residues Glu-286, Asp-363, and Asn-368. Analysis of kinase crystal structures as a function of crystallization buffer pH (Fig. S4C ) also suggests that an elevated pK a,in may occur in other kinases.
Combining standard literature estimates (35) and simulation results (see SI Text), we have estimated the contributions to ⌬G 233 and we find ⌬G 233 Ϸ Ϫ1.1 kcal/mol. The electrostatics calculations yield pK a,in Ϸ 6.6. With these estimates, Eq. 1 gives a large relative population of DFG-out conformations at pH Ϸ6 that decreases rapidly around pH Ϸ7 (Fig. 4B) . Although the estimated parameters are, of course, only semiquantitative, the basic conclusion of a near-balance in the free energies of DFG-in and DFG-out conformations close to physiological pH is robust to moderate changes in the parameters. Importantly, Eq. 1 shows that with a small ⌬G 233 , the DFG conformation becomes sensitive to changes in pK a,in and can thus be controlled by electrostatic changes in the ATP-binding site (we discuss the potential significance of this observation to kinase catalysis below). Similarly, our model predicts the effect of mutating Asp-381 or Phe-382 on DFG conformation; replacing Phe-382 with a less hydrophobic residue, for example, increases the relative population of DFG-out (Fig. 4B ).
Our energetic model should also be applicable to other kinases, most directly if their activation loops adopt the common open conformation (22, 36) in DFG-in and DFG-out states (as do Abl and c-Abl in PDB ID codes 2F4J (22) and 1OPK (7), respectively). Other activation-loop conformations-particularly those occluding substrate binding, as in Abl-imatinib complexes such as PDB ID code 1IEP (8)-can lead to solvent exposure of both Asp-381 and Phe-382. Such structures are found to adopt DFG-out conformations. This observation is consistent with our analysis, because the key factor stabilizing DFG-in conformations (the hydrophobic packing of Phe-382) is missing from these structures.
Probing the DFG-out Conformation by Using Abl-Imatinib Binding.
With imatinib bound, Abl adopts a DFG-out conformation (8) , suggesting that imatinib binding kinetics may provide a probe of DFG conformation. We derived the on-rate constant, k on , of imatinib binding to Abl as a function of pH by using stopped-flow fluorescence assays. As shown in Fig. 4A , k on for wild-type Abl decreases by nearly an order of magnitude as pH increases from 5.5 to 7.5, in which range imatinib is predominantly neutral (37). We observed a very similar pH dependence for a c-Abl construct containing its kinase and SH2-SH3 domains (Fig. S2 A) . However, control experiments showed the imatinib-binding kinetics for Abl mutants D381A and D381N to have essentially no dependence on pH over the same range (Fig. 4A) . The results for the mutants strongly suggest that the pH dependence observed for the wild type was a result of protonation at Asp-381.
Independent structural evidence supporting protonation of Asp-381 also exists. Most convincingly, the DFG-out c-Abl structure (PDB ID code 1OPK, resolution 1.8 Å, crystallized at pH 7.0) (7) shows 1 Asp-381 side-chain oxygen to be only 2.8 Å away from the Val-299 backbone carbonyl oxygen in a position that would be hard to rationalize if Asp-381 were not protonated in this structure. In addition, our analysis of the representative kinase structures (restricted to DFG-in conformations without bound ligands) shows that the distance of the DFG aspartate from the conserved lysine (Lys-271 in Abl) generally increases with decreasing pH of the crystallization buffer (Fig. S4C ). This suggests that protonation of the DFG aspartate may be common in protein kinases.
The above results provide strong evidence that the pK a of Asp-381 is significantly raised above typical values for aspartate residues. Because imatinib is a DFG-out binder (8) , another natural conclusion from the data is that protonation of Asp-381 favors DFG-out conformations. As a negative control, we have also performed fluorescence experiments using the DFG-in binder dasatinib (38, 39) . It is thought that so-called DFG-in binders typically bind to both DFG-in and DFG-out conformations (13) . We find only a very weak pH dependence for dasatinib binding (Fig.  4D) , consistent with the interpretation that the pH dependence observed for imatinib binding is a result of a pH-dependent DFG conformation.
More evidence supporting a link between protonation and DFG conformation comes from the pH dependence of imatinib binding to the Abl mutant F382A shown in Fig. 4A . This mutant shows a decrease in the imatinib on-rate constant with increasing pH, although the decrease is less pronounced and shifted to higher pH compared with the wild type. This implies a higher pK a for Asp-381 in the mutant, despite the fact that both phenylalanine and alanine are nonpolar and are positioned away from Asp-381, indicating that the mutation causes a conformational change and hence the elevated pK a . As explained above, an F382A mutation is predicted to lead to a larger population of DFG-out conformations, thus raising the pK a of Asp-381 in agreement with our experimental observations. Kinetic Scheme for Imatinib Binding. In contrast to its kinetics, the thermodynamics of Abl-imatinib binding determined from isothermal titration calorimetry (ITC) do not show a clear pH dependence (see Table S2 ). This is consistent with the observation made above that in the Abl-imatinib complex-unlike in the apo DFG-out conformation-Asp-381 is solvent-exposed (because of rearrangement of the activation loop on binding; see Fig. S5A ). To provide a quantitative explanation for the pH-dependent imatinib-binding kinetics, we propose the following kinetic scheme:
where Abl H and Abl Ϫ denote Abl with and without protonation of Asp-381. For the imatinib concentrations (Ͻ12.5 M) used in our experiments (discussed above), the fluorescence relaxation data fits a single-exponential decay, and the resultant relaxation rates are found to increase linearly with imatinib concentration (Fig. S6) . Under these conditions, we thus assume that the Asp-381-protonation and DFG-flip steps of the kinetic scheme (the leftmost and middle steps in Eq. 2, respectively) are fast compared with imatinib binding to the DFG-out conformation (rightmost step in Eq. 2). This leads to effective 1-step kinetics with an on-rate constant proportional to the population of the DFG-out state: k on ϭ P out k ϩ2 . In Fig. 4B , we show our estimates for P out (Eq. 1) as a function of pH for Abl and 3 mutants. These estimates are clearly consistent with our experimental results for k on , supporting our interpretation that the protonation of Asp-381 increases the population of DFG-out.
At sufficiently high imatinib concentrations, the rate of imatinib binding to the DFG-out conformation should become comparable with that of the DFG flip. In this case, the kinetic scheme leads to effective 2-step kinetics. This is consistent with the observed fluorescence decay rates, k obs , which are found to deviate from a linear dependence on imatinib concentration (see Fig. 4C ). In contrast, similar experiments for dasatinib binding showed no clear deviation from linearity (Fig. 4D) . These results clearly demonstrate an intermediate step in imatinib binding, and support the interpretation that the pH dependence of imatinib binding arises from the DFG flip. Detailed analysis of the kinetic data of imatinib binding also revealed the DFG-flip time scale to be in the tens of milliseconds (see SI Text), which is consistent with NMR studies of DFG dynamics (13) . This relatively long time scale may reflect the fact that the DFG flip involves conformational changes of the activation loop beyond the DFG motif itself (33) .
Conservation of the DFG Motif and Its Role in Kinase Catalysis.
Although the DFG aspartate is clearly important for catalysis, the roles of the phenylalanine and glycine residues and the reason for their conservation are much less certain (40) . Our results provide evidence that both of these residues may be essential to DFG conformational change. We find that the phenylalanine plays a key role in maintaining an energetic balance between the DFG-in and DFG-out states by compensating for the unfavorable DFG aspartate backbone torsion angles adopted in the DFG-in conformation. Our simulations also show that the DFG flip involves extensive backbone-torsion motions at the glycine residue, suggesting that the unique flexibility of glycine may serve to lower the kinetic barrier for the flip. This is consistent with work (41) suggesting that the DFG motif is optimized for functional dynamics rather than for structural stability, as is our finding that the DFG-out conformation can be populated under physiological conditions even in the absence of DFG-out binders.
If the DFG flip is to explain the conservation of the DFG motif, its role in kinase function must extend beyond the specific activation mechanism of c-Abl. The DFG flip has been suggested to promote ADP release (27) , the rate-limiting step in kinase catalysis (42) (43) (44) . Intriguingly, our results could be interpreted as hinting at a mechanistic explanation for such a proposed role. In ATP-bound kinases, the DFG aspartate interacts with a catalytically essential magnesium ion (Mg 2ϩ ) 2.3 Å away, which in turn coordinates the ␤ and ␥ phosphates of ATP (5) . Encouraged by observations on small G proteins (45, 46) showing that Mg 2ϩ binding is weakened by Ϸ3 orders of magnitude after transfer of the ␥ phosphate, we speculate that in kinases, this Mg 2ϩ may likewise be released after phosphate transfer, thus reducing the positive charge in the immediate vicinity of the DFG aspartate. If this is the case, we predict that this change in the electrostatic environment of the DFG aspartate would lead to its protonation-either from the solvent or through proton transfer from the catalytic base Asp-363-causing the motif to flip to a DFG-out conformation and thus facilitating ADP release. In such a scenario, nucleotide release could, in principle, be regulated by magnesium, consistent with the experimental observation that the ADP-release rate decreases with increasing Mg 2ϩ concentration (44) .
The DFG flip could facilitate ADP release, and potentially binding of the ATP-Mg 2ϩ complex, by allowing the kinase to adopt a DFG-out conformation, which we find to be significantly more flexible in terms of interlobe motions than the DFG-in conformation (Fig. S7) . This increased flexibility is consistent with the finding (32) that, in the active conformation, the DFG phenylalanine is part of the ''hydrophobic spine'' that lends stability to the DFG-in conformation. Although speculative, our suggestions are also consistent with kinetic data showing that at physiological Mg 2ϩ concentration, a 10-ms time scale conformational change follows ATP binding and precedes ADP release (44) , as well as with recent NMR titration experiments showing that upon the binding of ATP to PKA kinase, the DFG motif and nucleotide-binding loop of PKA exhibit microsecond to millisecond dynamics (31).
Conclusion
Using Abl as a model system, we have simulated the DFG flip, a conformational change known to be significant in a diverse set of kinases and, in particular, to be an important switch for c-Abl activation (7) . The simulations highlight the role of large-scale conformational changes in facilitating the DFG flip and point to the importance of the protonation of the DFG aspartate residue. This conclusion is supported experimentally by our Abl-imatinib binding assays, which reveal markedly pH-dependent binding kinetics. Our analysis shows that the DFG conformation is determined by a number of opposing factors that approximately balance, resulting in a DFG conformation sensitive to small changes in the electrostatics of the ATP-binding site. Combined with existing structural and kinetic data, this leads us to suggest that the conservation of the DFG motif stems from the DFG flip, which switches the kinase from the less-flexible DFG-in form required for catalysis to the more-flexible DFG-out form that facilitates nucleotide binding and release. The set of intermediate conformations observed in our simulations of the DFG flip may present new opportunities for inhibitor design. Furthermore, the pH sensitivity of the DFG conformation raises the possibility that local pH variations may play a role in kinase regulation in vivo.
Materials and Methods
Additional details are provided in SI Text.
Simulation Details. All simulations used the simple point charge (SPC) model for water (47) , the standard OPLS-AA parameters for ions (48, 49) , and the OPLS-AA/L force field for proteins (28, 29) as provided by the program IMPACT (50) (note that the relevant force-field option, referred to as OPLS2003 in the IMPACT paper, has subsequently been renamed as OPLS2005 in the actual program). All molecular dynamics simulations were performed by using the parallel MD program Desmond (19) on 64 or 128 dual-processor Opteron nodes connected by a high-speed Infiniband network (Topspin, San Jose, CA). Each simulation is represented by a code number that is given, along with other key simulation details, in Table S1 .
Kinetic Measurements of Drug Binding.
Wild-type human c-Abl kinase domain (residues 248 -532) and mutant proteins were generated and purified as described previously (51) . The drug-binding kinetics is measured by monitoring the decrease of protein fluorescence at 350 nm upon excitation at 290 nm on a HORIBA Jobin Yvon FluoroMax-3 spectrofluorimeter for 10 -20 half-lives of the transient, recorded by 1,000 -2,000 data points. where ⌬G 132 ϭ G 2 Ϫ G 1 and ⌬G 233 ϭ G 3 Ϫ G 2 are the free-energy differences between states (i) and (ii), and (ii) and (iii), respectively. ⌬G 132 is the free-energy cost to protonate Asp-381 in the DFG-in conformation,
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where pK a,in is the Asp-381 pK a value in the DFG-in conformation, which we estimated using electrostatic calculations (1) based on crystal structure 2F4J (with ligand removed) to be pK a,in ϭ 6.6. Based on the structural differences between the DFG-in and DFG-out conformations, we approximate ⌬G 233 as the sum of 4 terms:
where ⌬G is the free energy of DFG-out relative to DFG-in stemming from the strained aspartate -angles of the latter (see below), ⌬G Phe and ⌬G AspH are, respectively, the free energies of transferring phenylalanine and protonated aspartate side chains from a hydrophobic to a hydrophilic environment, and ⌬G HB is the free energy of the hydrogen bond of protonated Asp-381 to the backbone carbonyl group of Val-299 in the Abl DFG-out conformation. Replica-exchange molecular dynamics simulations (see below) of a ADFG tetrapeptide in explicit solvent yield an estimate of ⌬G ϭ Ϫ2.4 kcal/mol. The KyteDoolittle (KD) hydrophobicity scale (2) gives ⌬G Phe ϭ 2.8 kcal/mol. Because it refers to a residue protonated in both environments, ⌬G AspH is not directly given by the KD scale, we therefore approximate it based on the KD value for asparagine (⌬G Asn ϭ Ϫ3.5 kcal/mol); specifically ⌬G AspH ϭ ⌬G Asn ϩ 1.0 kcal/mol ϭ Ϫ2.5 kcal/mol, where the 1.0 kcal/mol is an estimate of the hydrophobicity difference between OH and NH 2 groups (3).
For the hydrogen bond we use the standard estimate ⌬G HB ϭ Ϫ4.0 kcal/mol (4). Inserting the estimated values into Eq. S3 yields ⌬G 233 ϭ Ϫ1.1 kcal/mol. From Eq. S1 the DFG-out population at 300 K is:
To apply the model to the F382A mutant, we assume pK a,in remains the same and replace ⌬G Phe ϭ 2. Estimation of ⌬G. ⌬G was estimated using replica-exchange molecular dynamics (REMD) (5) simulations of solvated ADFG tetrapeptide (the DFG motif is preceded by an alanine residue in Abl). The REMD simulations were performed using Desmond with force field and simulation parameters as described above, apart from the use of constant volume. The initial peptide conformation of the simulation was DFG-out, and obtained from a simulation of Abl which started in the conformation adopted by the kinase domain of PDB ID code 1OPK. Throughout the REMD simulation the N-C␣ bond of the alanine and the C␣-C bond of the glycine were fixed in space to restrict the DFG backbone to conformations similar to those accessible in the full kinase domain. The simulation system is a 27 ϫ 27 ϫ 27 Å 3 cube. Eight replicas (respectively at temperature of 300 K, 375 K, 450 K, 525 K, 600 K, 700 K, 800 K, and 900 K) were simulated for 308 ns. At a time interval of 10 ps, conformations of the DFG motif of the replica at 300 K were collected and classified into either DFG-in or DFG-out conformations based on simple geometric criteria.
Kinetic Scheme. Using the 3 different states that enter our energetic model, we propose the following kinetic scheme for imatinib binding to Abl:
The leftmost equilibrium between deprotonated and protonated forms of DFG-in is assumed to be kinetically negligible, i.e., extremely fast compared with the other steps, so that the kinetic scheme reduces to 2 steps:
where k* ϩ1 ϭ P AspH,in k ϩ1 , and P AspH,in ϭ (1 ϩ 10 pHϪpKa,in ) Ϫ1 is the probability in a DFG-in conformation that Asp-381 is protonated. This effective 2-step kinetic model has a fast and a slow rate constant. Assuming these have reasonably well-separated time scales, the slower rate constant, which is observed experimentally, is (6):
where here, instead of the notation [imatinib] used in the main text, we use L to denote the concentration of imatinib. Of course, for k Ϫ1 and k* ϩ1 much greater than k Ϫ2 and k ϩ2 L, this reduces to
We use this expression to fit the experimental k obs at low imatinib concentrations (Ͻ12.5 M). However, for the experiments performed over a wider range of imatinib concentrations, we assume only that k Ϫ1 , k* ϩ1 , and k ϩ2 L are much greater than k Ϫ2 , in which case Eq. S5 simplifies to
where ϭ (k* ϩ1 ϩ k Ϫ1 )/k ϩ2 . At each pH value, we independently perform 2-parameter fits of the measured rate constants as a function of imatinib concentration (Fig. 4C, main text) . That is, we use Eq. S6 with the pH-dependent and k* ϩ1 as fitting parameters. The nonlinear fit is performed using the NonlinearRegress function in Mathematica (7 Based on Eq. S6, however, a global 4-parameter (k ϩ1 , k Ϫ1 , k ϩ2 , and pK a,in ) fit of data at all pH values is unsatisfactory at high pH. This could be explained by the existence of a minority process that has a nonnegligible effect on k obs at high pH (where k obs is small):
where the asterisk indicates that the Abl-imatinib complex is structurally different from that formed by the majority process. This process could correspond to imatinib binding in an alternative mode to the DFG-in conformation, such as is known to occur in Syk kinase (8) .
With the assumption that k ϩ2 Ͼ Ͼ k ϩ3 Ͼ Ͼ k Ϫ3 , k obs becomes
(The meaning of the second term in Eq. S7 is clarified by the observation that when k ϩ2 L Ͻ Ͻ k Ϫ1 , this term reduces to k ϩ3 P in L, where
is the relative population of the DFG-in conformation with respect to the DFG-out.) Eq. S7, with global fitting parameters k ϩ1 , k Ϫ1 , k ϩ2 , k ϩ3 , and pK a,in , fits the data well over the entire pH range (Fig. S5B) . The nonlinear fit was performed using the NonlinearRegress function in Mathematica, and yielded k ϩ1 ϭ 54 Ϯ 24 s
, and pK a,in ϭ 7.1; the resultant DFG-flip timescale of 33 ms at pH 7.0 is almost identical to that derived from the independent 2-parameter fit described above.
Kinetic Scheme: Mathematical Details. For completeness, in this section we give a more detailed derivation of Eq. S7.
we have a kinetic scheme that depends on 4 rate constants (k* ϩ1 , k Ϫ1 , k ϩ2 , k ϩ3 ):
We assume excess ligand, i.e., that the concentration of imatinib, L, is well approximated by a constant. The kinetic scheme is then described by linear differential equations in time, t,
where C1, C2, C3, C4 denote concentrations of Abl(DFG-in), Abl(DFG-out), Abl-imatinib and (Abl-imatinib)*, respectively, and
The matrix A can be shown to have two nonzero eigenvalues, 1 and 2 , given by
The kinetic scheme thus formally leads to biexponential kinetics for Abl-imatinib binding with the two rate constants given by Ϫ 1 and Ϫ 2 . Our f luorescence experiments are well fit by a singleexponential decay, suggesting the fast rate is too fast to be resolved in the experiment; i.e., we are in the regime where k obs ϭ Ϫ 2 Ͻ Ͻ Ϫ 1 . In this regime, to a good approximation
. Thus,
Finally, under the assumption that k ϩ2 Ͼ Ͼ k ϩ3 and using the definition ϭ (k* ϩ1 )/k ϩ2 , this expression for k obs simplifies directly to that given in Eq. S7.
Additional Simulation Details. All simulation systems were set up using GROMACS tools (9, 10) , placing the kinase domain in the center of the simulation box and filling the voided space with water molecules. The proteins were oriented with their principal axes running parallel to the edges of the rectangular simulation boxes. The dimensions of the simulation boxes were chosen so that no protein atom was within 6 Å of the edge. Asp-381 was protonated or deprotonated as specified, while protonation states of other residues were set to their default values at pH 7. Na ϩ and Cl Ϫ ions were added to maintain physiological salinity (150 M) and to obtain a neutral total charge for the system. All systems were energy minimized using GROMACS 3.2.1 before simulation.
All molecular dynamics simulations were performed by using the parallel MD program Desmond (11) on 64 or 128 dualprocessor Opteron nodes connected by a high-speed Infiniband network (Topspin). Desmond employs a particular neutral territory method (12, 13) called the midpoint method (14) to efficiently exploit a high degree of computational parallelism. Long-range electrostatic interactions were computed by the Gaussian split-Ewald method (15) with a Fourier-space solver using a 64 ϫ 64 ϫ 64 mesh of spacing less than 1.5 Å. The Gaussian for charge spreading and force interpolation on the mesh had a standard deviation ( s ) of Ϸ1.0 Å (slightly varying with system size) and was truncated at 3.3 s . The Gaussian for k-space convolution with the charge distribution had a standard deviation between 1.7 and 1.9 Å. The real-space part of the electrostatic and Lennard-Jones interactions was cut off at 10 Å. The M-SHAKE algorithm was used to constrain the lengths of bonds containing hydrogen. All MD simulations were at constant pressure (1 bar), maintained using a Berendsen barostat, and constant temperature (300 K) maintained using Berendsen thermostats (16) . The pressure and temperature control used a relaxation time of 0.5 ps. All simulations used a RESPA integrator (17) with a 2.5-fs time step for the bonded, van der Waals and short-range Coulomb interactions, and a 5-fs time step for the long-range Coulomb interactions. By introducing an orientational potential, the overall orientation of the protein was restrained with its principal axes held approximately parallel to the edges of the simulation box throughout the simulation.
Each simulation is represented by a code number that is given, along with other key simulation details, in Table S1 . The human c-Abl kinase domain we simulated consists of residues 230 to 512 inclusive. All simulations based on PDB ID code 2F4J (i.e., simulations 1-7 inclusive) contain the H396P mutation present in that structure. Simulation 8 was based on the kinase domain of PDB ID code 1OPK, and contains the D363N mutation present in that structure. There are no bound ligands in any simulation. All simulations involving the M290A mutation also contain the W235A mutation. Trp-235 is a solvent-exposed residue located close to the N terminus of the kinase domain of c-Abl, and Ϸ17 Å away from the center of the DFG motif. To avoid possible complications of this tryptophan residue playing a role in inhibition (which it is known to do in c-Src when the SH2 and SH3 domains are present (18)), we mutated it to alanine in our simulations of the DFG flip in Abl.
Computational Estimation of the pKa for Asp-381. We used the Hϩϩ pK a calculation server (http://biophysics.cs.vt.edu/Hϩϩ) to estimate the pK a values of Asp-381 in DFG-in and DFG-out conformations. The former was estimated based on an active Abl structure (PDB ID code 2F4J), whereas the latter was based on an autoinhibited c-Abl structure (PDB ID code 1OPK) with the regulatory domains removed from the original structure. The pK a of Asp-381 in the DFG-in conformation is estimated to be 6.6, whereas the pK a of Asp-381 in the DFG-out conformation was estimated to be 11.7. This is consistent with the notion that under physiological pH, whereas Asp-381 protonation is common in the DFG-in conformation, it is inherent in the DFG-out conformation.
Additional Details of the Kinetic Measurements of Drug Binding. For the measurement of drug-binding kinetics, we mixed equal volumes of the kinase domain at 100 nM concentration with drug solutions at concentrations ranging from 1 M to 200 M for imatinib and 1-25 M for dasatinib. For each individual binding transient, we mixed a total of 700 l of reactants in a rapid mixing instrument (Applied Photophysics) with a typical instrumental dead time of Ϸ10 ms. The decrease of protein fluorescence at 350 nm upon excitation at 290 nm was monitored on a HORIBA Jobin Yvon FluoroMax-3 spectrofluorimeter for 10-20 half-lives of the transient recorded by 1000-2000 datapoints. The buffer conditions for the experiments were 50 mM Tris (pH range 7.0-9.0) or Bis-Tris (pH range 5.5-6.5), 100 mM NaCl, 1 mM DTT, 5% DMSO. The experiment at high imatinib concentration (Fig. 4C ) was carried out with 5% glycerol at 298 K, whereas the experiment at low imatinib concentration (Fig. 4A ) was carried out with 15% glycerol at 283 K.
To confirm fast binding events, we also recorded binding transients on a Hi-Tech KinetAsyst stopped-flow instrument with a typical instrumental dead time of Ϸ1-5 ms under identical experimental conditions. The results from both experimental systems were identical.
We recorded at least 3 transients for each experimental condition. Each transient was fitted individually to a single exponential of the form
Here F is the amplitude of the change in fluorescence upon drug binding, k obs is the observed rate constant, t is the time of the reaction, m is the slope of the baseline, and F Eq is the fluorescence at equilibrium. For reactions shorter than 5 sec, the analysis of the residuals of the single-exponential fit did not warrant the inclusion of a sloping baseline in the data fit to account for photobleaching of the tryptophan fluorescence. Observed rate constants were plotted against the final concentration of the drug. For a simple two-state binding process under pseudo first-order conditions, the relationship between the observed rate constant and the ligand concentration is expected to be linear:
Here k on is the rate constant for the binding reaction, k off is the rate constant for the dissociation reaction and [drug] is the drug concentration (19) .
Measurement of Protein-Drug Interaction at Equilibrium. We measured protein-drug interaction under equilibrium conditions by isothermal titration calorimetry on a MicroCal VP-ITC (MicroCal) essentially as described before (20, 21) . Proteins were buffer exchanged into 50 mM Tris, 100 mM NaCl, 0.5 mM TCEP, 15% glycerol, 5% DMSO at pH 5.5-7.5. Imatinib stocks were diluted in the same buffer to 250 M final concentration and titrated to protein at 10-30 M concentration at 25°C. Data were fitted to the single binding site model with the Origin software package (OriginLab). The results are given in Table S2 .
Measurement of the Enzymatic Activity of Src M314A (Corresponding to Abl M290A) Mutant. Activity of the protein kinases toward the optimal Abl substrate peptide (sequence: EAIYAAPFAKKK) (22) was determined using a continuous spectrophotometric assay, as previously described (23) . The Michaelis-Menten constant (K m ) for the kinase substrate ATP and the maximum catalytic constant k cat max were determined by fitting the observed catalytic rates to the Michaelis-Menten equation (Fig. S2B) :
We observed that high ATP concentrations decrease kinase activity and therefore we added a sloping baseline-the linear term-to correct for this deviation.
The Representative Kinase Structure Set. The representative kinase structure set used in this study was compiled by Nolen et al. (24) . We have added structures 2F4J (Abl in an active DFG-in conformation) and 1OPK (c-Abl in an inactive DFG-out conformation) to the original set. The set thus contains 25 active kinase structures and 33 inactive kinase structures. In Fig. S2 , the data are from 25 active DFG-in structures (PDB entries 1ATP,  1CKJ, 1CM8, 1DAW, 1H1W, 1H4L, 1HOW, 1IA8, 1IR3, 1JKK,  1JOW, 1K3A, 1K9A, 1M14, 1MRU, 1O6K, 1O9U, 1OL5,  1PKG, 1QMZ, 1VR2, 2ERK, 2F4J, 2PHK, 3LCK), 26 inactive  DFG-in structures (1A06, 1AD5, 1B6C, 1ERK, 1F3M, 1FGK,  1FMK, 1H8F, 1HCK, 1JNK, 1JPA, 1K2P, 1KOB, 1M7N, 1MQB,  1MRY, 1MUO, 1NY3, 1O6K, 1OL5, 1OMW, 1P38, 1QMZ , 1R1W, 1TKI, 1UKH) and 7 inactive DFG-out structures (1FVR, 1IRK, 1LUF, 1OPK, 1RJB, 1T45, 1UWH). Fig. S5 includes only DFG-in structures without ligands bound in or near the ATPbinding site, and comprises 10 active structures (1CKJ, 1H4L, 1IA8, 1JOW, 1K9A, 1M14, 1O9U, 1VR2, 2ERK, 3LCK) and 8 inactive structures (1A06, 1F3M, 1FGK, 1M7N, 1P38, 1R1W , 1TKI, 1UKH). 
Movie S1 (MPG)
Movie S1. This movie shows a trajectory of a DFG flip starting from the DFG-in and ending at the DFG-out conformation. The DFG aspartate and phenylalanine (Asp-381 and Phe-382) are shown with red and green van der Waals surfaces, respectively. The Abl kinase domain is shown as a ribbon. This trajectory is a concatenation of simulation 4a (first 2 ns) and simulations 6b (fist 85 ns), as described in the main text. Simulations with the same code number but different letters differ only in their initial thermal velocities, which were assigned randomly. The protonation state of Asp381 is denoted COO Ϫ (deprotonated) or COOH (protonated). The DFG conformation ЉN-pocketЉ denotes a DFG-in conformation in which Phe382 has moved into the N-pocket as discussed in the text. For simulations 3 a-e, the 210-ns figure that appears in the ЉLengthЉ column represents the aggregate length of all 5 simulations. Here, N refers to the stoichiometry of the binding, ⌬G the binding free energy, ⌬H and T⌬S its enthalpic and entropic contributions, and KD the equilibrium dissociation constant. We find that the affinity of Abl kinase domain for imatinib is independent of the pH over the pH range studied, which indicates that the relative stability of the drug-bound and drug-free state is unaltered by pH.
